Viatris Inc vs Yum! Brands, Inc. — how do they compare? Viatris Inc trades at $16.45 (market cap $19.09B), while Yum! Brands, Inc. trades at $144.94 (market cap $40.80B). The key difference: Yum! Brands, Inc. is far larger — about 2.1× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.89%). Which is the better fit depends on your goals.
| VTRS | YUM | |
|---|---|---|
Market Cap | $19.09B | $40.80B |
Sector | Health | Consumer Cyclical |
52-Week High | $17.86 | $168.16 |
52-Week Low | $9.49 | $138.21 |
Enterprise Value | $31.21B | $52.40B |
Dividend Yield | 2.89% | 2.01% |
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $16.61, down 1.6% over the past 24 hours. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported a net loss of $3.51 billion in 2025 despite revenue of $14.30 billion, though recent quarters have shown earnings beats. Positive cash flow generation and a dividend payment highlight financial stability, while analyst sentiment is mixed with a majority hold rating.
The outlook for VTRS hinges on its ability to return to profitability and sustain operational improvements. Investment opportunities include strong cash flow, deleveraging progress, and pipeline developments, but risks involve persistent net losses, competitive pressures, and potential regulatory impacts from proposed generic drug tariffs.
YUM trades at $149.59, down 0.74% on the day, with a bearish technical signal and neutral oscillators. The company reported revenue of $8.21B and net income of $1.56B in 2025, with a P/E ratio of 18.83. Recent developments include the sale of Pizza Hut for approximately $1.5B to LongRange Capital, with proceeds aimed at debt reduction and share buybacks, alongside a declared $0.75 quarterly dividend.
The outlook is mixed: analyst consensus is a buy with a $173.60 price target, but high debt and a legal investigation pose risks. Earnings have beaten expectations in two of the last three quarters, with Q3 2026 results pending. The stock offers potential upside from strategic refocusing and buybacks, balanced against consumer spending pressures and leverage concerns.
Trailing returns across standard periods
Latest headlines on both assets
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →